The ELMA trial, sponsored by Rigshospitalet, Denmark, investigates the role of postoperative exercise training in patients undergoing surgery for colorectal liver metastases (CRLM). Given the high incidence of colorectal cancer and the associated poor prognosis of CRLM, successful outcomes from this trial could position exercise training as a standard adjunctive therapy in surgical oncology, potentially enhancing recovery and reducing long-term disease progression. The market for supportive cancer therapies is growing, and positive results could lead to partnerships with healthcare providers and fitness organizations, as well as opportunities for commercialization of exercise programs tailored for cancer patients. However, the trial's non-drug nature may limit traditional pharmaceutical investment interest, necessitating a focus on collaborations with rehabilitation and oncology-focused entities.